NASDAQ:BLUE - bluebird bio Stock Price, Price Target & More

$170.50 0.00 (0.00 %)
(As of 04/20/2018 04:00 PM ET)
Previous Close$170.50
Today's Range$168.20 - $172.85
52-Week Range$74.45 - $236.17
Volume468,795 shs
Average Volume847,258 shs
Market Capitalization$8.73 billion
P/E Ratio-22.11
Dividend YieldN/A

About bluebird bio (NASDAQ:BLUE)

bluebird bio logobluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease. The company's lead product candidates in oncology include bb2121 and bb21217, which are anti- B-cell maturation antigens in Phase I clinical trials for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology. It also has collaborations with Medigene AG for the research and development of T cell receptor product candidates directed against antigens for the treatment of cancer indications; and TC BioPharm Limited to research and develop gamma delta chimeric antigen receptor modified T cell product candidates for cancer immunotherapy, as well as a partnership agreement with Celgene European Investment Company LLC. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.

Receive BLUE News and Ratings via Email

Sign-up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic


Debt-to-Equity RatioN/A
Current Ratio13.84%
Quick Ratio13.83%


Trailing P/E Ratio-22.11
Forward P/E Ratio-20.23
P/E GrowthN/A

Sales & Book Value

Annual Sales$35.43 million
Price / Sales240.52
Cash FlowN/A
Price / CashN/A
Book Value$33.11 per share
Price / Book5.15


EPS (Most Recent Fiscal Year)($7.71)
Net Income$-335,640,000.00
Net Margins-947.42%
Return on Equity-28.09%
Return on Assets-23.00%


Outstanding Shares49,980,000

How to Become a New Pot Stock Millionaire

bluebird bio (NASDAQ:BLUE) Frequently Asked Questions

What is bluebird bio's stock symbol?

bluebird bio trades on the NASDAQ under the ticker symbol "BLUE."

How were bluebird bio's earnings last quarter?

bluebird bio (NASDAQ:BLUE) announced its earnings results on Wednesday, February, 21st. The biotechnology company reported ($2.52) EPS for the quarter, missing the Zacks' consensus estimate of ($1.68) by $0.84. The biotechnology company earned $4.17 million during the quarter, compared to analysts' expectations of $7.11 million. bluebird bio had a negative return on equity of 28.09% and a negative net margin of 947.42%. bluebird bio's revenue for the quarter was up 169.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.88) EPS. View bluebird bio's Earnings History.

When is bluebird bio's next earnings date?

bluebird bio is scheduled to release their next quarterly earnings announcement on Tuesday, May, 1st 2018. View Earnings Estimates for bluebird bio.

What price target have analysts set for BLUE?

23 brokers have issued 12-month price objectives for bluebird bio's shares. Their predictions range from $102.00 to $250.00. On average, they expect bluebird bio's share price to reach $199.7368 in the next year. View Analyst Ratings for bluebird bio.

What are Wall Street analysts saying about bluebird bio stock?

Here are some recent quotes from research analysts about bluebird bio stock:
  • 1. According to Zacks Investment Research, "Bluebird Bio, Inc. is a biotechnology company. It focuses on the development, manufacture and marketing of therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders and beta-thalassemia. The company operates in the U.S. and Europe. Bluebird Bio, Inc. is headquartered in Cambridge, Massachusetts. " (3/20/2018)
  • 2. Maxim Group analysts commented, "bluebird reported YE-2017 with $22M in revenue (collaborative/licensing revenue) and a net loss of $336M. Operating expenses have increased as clinical programs advance to later stages of development. The company ended the period with $1.6B in cash, sufficient runway into 2021 at the current burn rate." (2/22/2018)
  • 3. Cantor Fitzgerald analysts commented, "Lining Up for Three Marketing Applications. bluebird plans to file for European approval of LentiGlobin in transfusion-dependent b-thalassemia (non-b0/b0) in 2H18, followed by bb2121 in relapsed/refractory multiple myeloma and Lenti-D in cerebral adrenoleukodystrophy in 2019. As a reminder, bb2121 is being investigated in a Phase 3 study, KarMMa, which is being conducted by bluebird’s bb2121 development partner, Celgene (CELG – Neutral, covered by Mara Goldstein)." (2/21/2018)
  • 4. Morgan Stanley analysts commented, "excitement." But now may be a time for investors to turn cautious, at least according to analysts at Morgan Stanley. The firm's Matthew Harrison downgraded Bluebird's stock rating from Equal Weight to Underweight with an unchanged $105 price target.Heading into the end of 2017 there are underappreciated risks that the Street may be ignoring, Harrison commented. Specifically, data related to LentiGlobin sickle cell data is unlikely to show any significant improvement in hemoglobin production that will be good enough to "increase investor confidence" in its sickle cell gene therapy."Based on prior data, our premise is that to improve hemoglobin production in sickle cell patients, the correlation between drug-product vector copy number (DP VCN) and peripheral VCN (pVCN) needs to increase substantially," the analyst explained. "We do not believe the evidence supports current investor optimism that this can be solved by ASH." (10/2/2017)

Who are some of bluebird bio's key competitors?

Who are bluebird bio's key executives?

bluebird bio's management team includes the folowing people:
  • Mr. Nick Leschly, Pres, CEO & Director (Age 45)
  • Mr. Jeffrey T. Walsh, Chief Financial & Strategy Officer and Treasurer (Age 52)
  • Ms. Susanna Gatti High, Chief Operating Officer (Age 50)
  • Dr. Philip D. Gregory D. Phil., Chief Scientific Officer (Age 47)
  • Dr. David M. Davidson M.D., Chief Medical Officer (Age 54)

Has bluebird bio been receiving favorable news coverage?

News coverage about BLUE stock has been trending somewhat negative on Friday, Accern Sentiment Analysis reports. The research group scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. bluebird bio earned a daily sentiment score of -0.01 on Accern's scale. They also assigned media stories about the biotechnology company an impact score of 47.80 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future.

How do I buy shares of bluebird bio?

Shares of BLUE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is bluebird bio's stock price today?

One share of BLUE stock can currently be purchased for approximately $170.50.

How big of a company is bluebird bio?

bluebird bio has a market capitalization of $8.73 billion and generates $35.43 million in revenue each year. The biotechnology company earns $-335,640,000.00 in net income (profit) each year or ($7.71) on an earnings per share basis. bluebird bio employs 479 workers across the globe.

How can I contact bluebird bio?

bluebird bio's mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 339-499-9300 or via email at [email protected]

MarketBeat Community Rating for bluebird bio (BLUE)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  668 (Vote Outperform)
Underperform Votes:  279 (Vote Underperform)
Total Votes:  947
MarketBeat's community ratings are surveys of what our community members think about bluebird bio and other stocks. Vote "Outperform" if you believe BLUE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BLUE will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

bluebird bio (NASDAQ:BLUE) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
23 Wall Street analysts have issued ratings and price targets for bluebird bio in the last 12 months. Their average twelve-month price target is $199.7368, suggesting that the stock has a possible upside of 17.15%. The high price target for BLUE is $250.00 and the low price target for BLUE is $102.00. There are currently 3 sell ratings, 8 hold ratings and 12 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldBuyHold
Consensus Rating Score: 2.392.392.502.45
Ratings Breakdown: 3 Sell Rating(s)
8 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
8 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
7 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
5 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $199.7368$199.2632$159.5263$118.8553
Price Target Upside: 17.15% upside4.88% upside6.02% downside9.75% downside

bluebird bio (NASDAQ:BLUE) Consensus Price Target History

Price Target History for bluebird bio (NASDAQ:BLUE)

bluebird bio (NASDAQ:BLUE) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/19/2018SunTrust BanksBoost Price TargetBuy$232.00HighView Rating Details
3/28/2018Canaccord GenuityReiterated RatingBuyLowView Rating Details
3/21/2018Morgan StanleyBoost Price TargetEqual Weight -> Equal Weight$152.00 -> $209.00HighView Rating Details
3/16/2018William BlairReiterated RatingBuyMediumView Rating Details
3/16/2018UBSInitiated CoverageSellHighView Rating Details
3/14/2018Janney Montgomery ScottInitiated CoverageNeutral -> Neutral$220.00MediumView Rating Details
3/8/2018BTIG ResearchBoost Price TargetBuy$250.00MediumView Rating Details
2/22/2018Maxim GroupReiterated RatingHold$200.00MediumView Rating Details
2/22/2018Bank of AmericaBoost Price TargetNeutral -> Neutral$185.00 -> $218.00MediumView Rating Details
2/22/2018BMO Capital MarketsSet Price TargetOutperform -> Buy$215.00 -> $222.00HighView Rating Details
2/22/2018Sanford C. BernsteinReiterated RatingHold$153.00 -> $211.00HighView Rating Details
2/22/2018Cantor FitzgeraldLower Price TargetUnderweight$122.00 -> $113.00HighView Rating Details
1/25/2018Leerink SwannDowngradeOutperform -> Market Perform$162.00 -> $194.00LowView Rating Details
1/9/2018OppenheimerReiterated RatingHoldLowView Rating Details
12/21/2017CIBCInitiated CoverageMarket Perform -> Market PerformHighView Rating Details
12/13/2017BarclaysReiterated RatingOverweight -> Overweight$162.00 -> $209.00HighView Rating Details
12/12/2017Wells FargoReiterated RatingOutperform$190.00 -> $242.00HighView Rating Details
12/11/2017Jefferies GroupUpgradeHold -> Buy$130.00 -> $211.00HighView Rating Details
11/2/2017WedbushReiterated RatingOutperform$135.00 -> $174.00N/AView Rating Details
10/16/2017Evercore ISIUpgradeIn-Line -> Outperform$102.00N/AView Rating Details
10/6/2017Goldman SachsReiterated RatingBuy -> Buy$186.00N/AView Rating Details
8/31/2017CowenReiterated RatingOutperformHighView Rating Details
6/16/2017Standpoint ResearchReiterated RatingBuy -> Reduce$110.00LowView Rating Details
2/23/2017Roth CapitalSet Price TargetHold$71.00N/AView Rating Details
12/7/2016JPMorgan ChaseReiterated RatingBuy$120.00N/AView Rating Details
11/30/2016Piper JaffrayReiterated RatingOverweight$95.00N/AView Rating Details
(Data available from 4/20/2016 forward)


bluebird bio (NASDAQ:BLUE) Earnings History and Estimates Chart

Earnings by Quarter for bluebird bio (NASDAQ:BLUE)

bluebird bio (NASDAQ:BLUE) Earnings Estimates

2018 EPS Consensus Estimate: ($8.23)
2019 EPS Consensus Estimate: ($8.79)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20185($2.26)($1.77)($2.01)
Q2 20185($2.16)($1.79)($2.02)
Q3 20185($2.18)($1.79)($2.08)
Q4 20185($2.23)($1.80)($2.12)
Q1 20192($2.31)($2.31)($2.31)
Q2 20192($2.45)($2.40)($2.43)
Q3 20191($2.07)($2.07)($2.07)
Q4 20191($1.98)($1.98)($1.98)

bluebird bio (NASDAQ BLUE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/1/2018($2.01)N/AView Earnings Details
2/21/2018Q4 2017($1.68)($2.52)$7.11 million$4.17 millionViewN/AView Earnings Details
11/1/2017Q3 2017($1.68)($1.7260)$8.47 million$7.71 millionViewN/AView Earnings Details
8/2/2017Q2 2017($1.66)($1.73)$6.29 million$16.70 millionViewN/AView Earnings Details
5/3/2017Q1 2017($1.7610)($1.68)$1.51 million$6.83 millionViewN/AView Earnings Details
2/22/2017Q4 2016($1.86)($1.88)$1.76 million$1.55 millionViewN/AView Earnings Details
11/2/2016Q3 2016($1.59)($2.07)$1.82 million$1.55 millionViewN/AView Earnings Details
8/3/2016Q2($1.44)($1.59)$2.01 million$1.55 millionViewN/AView Earnings Details
5/4/2016Q1($1.23)($1.52)$4.50 million$1.50 millionViewN/AView Earnings Details
2/24/2016Q4($1.11)($1.29)$3.21 million$1.47 millionViewN/AView Earnings Details
11/4/2015Q3($0.96)($1.18)$5.63 million$1.30 millionViewListenView Earnings Details
8/6/2015Q215($0.78)($1.57)$8.60 million$4.94 millionViewN/AView Earnings Details
5/6/2015Q115($0.68)($0.76)$6.20 million$6.30 millionViewN/AView Earnings Details
2/25/2015Q414($0.62)($0.66)$6.20 million$6.30 millionViewN/AView Earnings Details
11/12/2014Q314($0.52)($0.61)$6.20 million$6.40 millionViewN/AView Earnings Details
8/12/2014Q214($0.45)($0.06)$6.15 million$6.30 millionViewN/AView Earnings Details
5/13/2014Q114($0.32)($0.44)$6.23 million$6.30 millionViewN/AView Earnings Details
3/5/2014($0.31)($0.34)$6.20 million$6.34 millionViewN/AView Earnings Details
11/12/2013Q3($0.25)($0.26)$5.59 million$6.39 millionViewN/AView Earnings Details
8/8/2013Q213($0.35)($2.13)$4.85 million$6.30 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


bluebird bio (NASDAQ:BLUE) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

bluebird bio (NASDAQ BLUE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.90%
Insider Trading History for bluebird bio (NASDAQ:BLUE)
Institutional Ownership by Quarter for bluebird bio (NASDAQ:BLUE)

bluebird bio (NASDAQ BLUE) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/12/2018David DavidsonInsiderSell3,000$180.17$540,510.0027,905View SEC Filing  
4/2/2018David DavidsonInsiderSell22,000$167.52$3,685,440.00View SEC Filing  
3/15/2018Mark VachonDirectorSell6,000$214.38$1,286,280.007,000View SEC Filing  
3/1/2018Philip D GregoryInsiderSell2,250$200.00$450,000.0032,522View SEC Filing  
2/2/2018David DavidsonInsiderSell4,000$202.36$809,440.00View SEC Filing  
1/30/2018Jason ColeInsiderSell25,000$195.91$4,897,750.0044,798View SEC Filing  
1/30/2018Susanna Gatti HighCOOSell17,262$195.91$3,381,798.4228,512View SEC Filing  
1/8/2018David DavidsonInsiderSell3,522$173.61$611,454.4213,959View SEC Filing  
1/5/2018Jason ColeInsiderSell1,129$173.38$195,746.0219,945View SEC Filing  
1/5/2018Nick LeschlyCEOSell5,435$173.38$942,320.30171,009View SEC Filing  
1/3/2018David DavidsonInsiderSell6,000$180.30$1,081,800.0021,977View SEC Filing  
12/13/2017Nick LeschlyInsiderSell117,500$184.08$21,629,400.00293,232View SEC Filing  
12/11/2017Jeffrey T WalshInsiderSell9,900$216.54$2,143,746.0037,205View SEC Filing  
12/11/2017Mark VachonDirectorSell7,000$216.64$1,516,480.008,000View SEC Filing  
12/1/2017Philip D GregoryInsiderSell2,250$172.54$388,215.0028,734View SEC Filing  
12/1/2017Susanna Gatti HighCOOSell1,282$172.15$220,696.3013,718View SEC Filing  
11/10/2017Jeffrey T WalshInsiderSell9,900$149.58$1,480,842.0028,798View SEC Filing  
11/1/2017Jeffrey T WalshInsiderSell35,000$151.38$5,298,300.0062,305View SEC Filing  
11/1/2017Nick LeschlyCEOSell2,127$145.17$308,776.59257,486View SEC Filing  
10/23/2017Nick LeschlyInsiderSell7,050$145.14$1,023,237.00259,059View SEC Filing  
10/20/2017Nick LeschlyCEOSell3,350$145.02$485,817.00259,059View SEC Filing  
10/17/2017Nick LeschlyCEOSell10,823$145.05$1,569,876.15262,409View SEC Filing  
10/10/2017Jeffrey T WalshInsiderSell4,900$129.94$636,706.00View SEC Filing  
10/2/2017David DavidsonInsiderSell4,000$131.31$525,240.00View SEC Filing  
9/14/2017John MaraganoreDirectorSell18,868$131.21$2,475,670.2824,711View SEC Filing  
9/12/2017Mark VachonDirectorSell6,000$126.82$760,920.008,000View SEC Filing  
9/11/2017Jeffrey T WalshInsiderSell4,900$125.73$616,077.0032,205View SEC Filing  
9/1/2017Nick LeschlyInsiderSell46,833$122.27$5,726,270.91289,368View SEC Filing  
8/31/2017Daniel LynchDirectorSell500$120.00$60,000.003,300View SEC Filing  
8/31/2017Jeffrey T WalshInsiderSell12,000$125.01$1,500,120.0039,305View SEC Filing  
8/30/2017Nick LeschlyInsiderSell25,667$115.18$2,956,325.06339,368View SEC Filing  
8/28/2017Jeffrey T WalshInsiderSell1,250$107.06$133,825.0028,555View SEC Filing  
8/14/2017James MandellDirectorSell1,000$95.95$95,950.001,000View SEC Filing  
8/10/2017Jeffrey T WalshInsiderSell1,250$95.41$119,262.5028,555View SEC Filing  
8/7/2017Philip D GregoryInsiderSell750$99.00$74,250.0031,234View SEC Filing  
8/4/2017Eric SullivanInsiderSell861$93.83$80,787.635,924View SEC Filing  
8/1/2017David DavidsonInsiderSell3,000$92.37$277,110.0018,977View SEC Filing  
7/10/2017Jeffrey T WalshInsiderSell2,500$99.89$249,725.0029,805View SEC Filing  
7/7/2017David DavidsonInsiderSell1,200$100.49$120,588.0016,077View SEC Filing  
7/6/2017Philip D GregoryInsiderSell2,250$103.83$233,617.5033,734View SEC Filing  
7/5/2017David DavidsonInsiderSell5,000$105.28$526,400.0022,177View SEC Filing  
6/29/2017Eric SullivanInsiderSell6,787$108.96$739,511.528,466View SEC Filing  
6/27/2017Nick LeschlyInsiderSell25,000$108.05$2,701,250.00360,656View SEC Filing  
6/23/2017Daniel LynchDirectorSell4,000$109.09$436,360.004,808View SEC Filing  
6/20/2017Daniel LynchDirectorSell2,500$120.03$300,075.005,300View SEC Filing  
6/7/2017Jason ColeInsiderSell17,245$100.22$1,728,293.9030,871View SEC Filing  
6/6/2017Daniel LynchDirectorSell2,263$100.14$226,616.823,663View SEC Filing  
6/6/2017Philip D GregoryInsiderSell1,500$99.04$148,560.0037,279View SEC Filing  
6/5/2017David DavidsonInsiderSell1,000$90.00$90,000.0018,177View SEC Filing  
5/25/2017Daniel LynchDirectorSell2,000$80.00$160,000.003,400View SEC Filing  
4/27/2017Daniel LynchDirectorSell1,000$90.01$90,010.002,400View SEC Filing  
4/25/2017Daniel LynchDirectorSell2,000$86.75$173,500.003,400View SEC Filing  
4/10/2017Jeffrey T WalshInsiderSell1,250$87.38$109,225.0028,555View SEC Filing  
4/3/2017David DavidsonInsiderSell3,000$90.89$272,670.0020,177View SEC Filing  
3/27/2017Daniel LynchDirectorSell3,000$88.12$264,360.003,400View SEC Filing  
3/16/2017Daniel LynchDirectorSell237$100.07$23,716.591,637View SEC Filing  
3/16/2017Jason ColeInsiderSell4,930$100.07$493,345.1016,981View SEC Filing  
3/3/2017John MaraganoreDirectorSell13,839$85.02$1,176,591.785,765View SEC Filing  
2/15/2017Daniel LynchDirectorSell150$80.22$12,033.001,550View SEC Filing  
2/15/2017Jason ColeInsiderSell666$80.22$53,426.5212,051View SEC Filing  
2/14/2017Daniel LynchDirectorSell850$80.01$68,008.502,250View SEC Filing  
2/14/2017Jason ColeInsiderSell3,772$80.01$301,797.7212,717View SEC Filing  
1/31/2017James MandellDirectorSell8,000$75.04$600,320.009,000View SEC Filing  
1/27/2017Daniel LynchDirectorSell1,000$70.09$70,090.002,400View SEC Filing  
1/27/2017David DavidsonInsiderSell6,000$69.02$414,120.0014,677View SEC Filing  
1/5/2017Jason ColeInsiderSell549$67.10$36,837.909,389View SEC Filing  
10/3/2016Eric SullivanInsiderSell416$67.00$27,872.005,891View SEC Filing  
9/13/2016Eric SullivanInsiderSell416$59.00$24,544.005,891View SEC Filing  
8/3/2016Eric SullivanInsiderSell416$59.00$24,544.005,891View SEC Filing  
7/27/2016Eric SullivanInsiderSell2,912$55.01$160,189.124,456View SEC Filing  
7/20/2016Eric SullivanInsiderSell2,807$45.04$126,427.284,656View SEC Filing  
7/15/2016David DavidsonInsiderSell1,000$45.08$45,080.0010,600View SEC Filing  
6/16/2016Philip D GregoryInsiderSell2,931$39.52$115,833.1230,069View SEC Filing  
6/15/2016David DavidsonInsiderSell1,000$40.11$40,110.0010,600View SEC Filing  
5/16/2016David DavidsonInsiderSell1,000$38.73$38,730.0010,600View SEC Filing  
4/15/2016David DavidsonInsiderSell1,000$49.63$49,630.0010,600View SEC Filing  
3/15/2016David DavidsonInsiderSell1,000$46.13$46,130.0010,600View SEC Filing  
2/16/2016David DavidsoninsiderSell1,000$45.18$45,180.001,000View SEC Filing  
1/15/2016David DavidsoninsiderSell1,000$44.39$44,390.00View SEC Filing  
12/15/2015David DavidsoninsiderSell1,000$58.55$58,550.00View SEC Filing  
12/8/2015Nick LeschlyCEOBuy9,682$51.75$501,043.50313,241View SEC Filing  
11/16/2015David DavidsoninsiderSell2,000$70.99$141,980.00View SEC Filing  
11/10/2015Jeffrey T. WalshCOOSell11,000$74.60$820,600.00View SEC Filing  
10/15/2015David DavidsoninsiderSell2,000$79.70$159,400.00View SEC Filing  
10/12/2015Jeffrey T. WalshCOOSell11,000$88.06$968,660.00View SEC Filing  
10/9/2015Jason ColeSVPSell5,000$86.91$434,550.00View SEC Filing  
10/5/2015Daniel LynchDirectorSell3,000$100.41$301,230.00View SEC Filing  
9/17/2015Daniel LynchDirectorSell1,500$140.06$210,090.00View SEC Filing  
9/15/2015David DavidsoninsiderSell2,000$129.98$259,960.00View SEC Filing  
9/10/2015Jeffrey T. WalshCOOSell11,000$130.02$1,430,220.00View SEC Filing  
9/9/2015Jason ColeSVPSell2,000$136.56$273,120.00View SEC Filing  
9/8/2015Daniel LynchDirectorSell7,000$132.75$929,250.00View SEC Filing  
9/8/2015Nick LeschlyCEOSell125,000$135.24$16,905,000.00246,521View SEC Filing  
9/1/2015James MandellDirectorSell1,500$125.96$188,940.00View SEC Filing  
7/20/2015Eric SullivanInsiderSell1,126$163.36$183,943.36View SEC Filing  
7/15/2015David DavidsonInsiderSell2,000$165.96$331,920.00View SEC Filing  
7/10/2015Jeffrey T WalshCOOSell11,000$158.63$1,744,930.00View SEC Filing  
7/9/2015Jason ColeSVPSell5,000$158.19$790,950.00View SEC Filing  
6/15/2015David DavidsonInsiderSell2,000$183.34$366,680.00View SEC Filing  
6/10/2015Jeffrey T WalshCOOSell11,000$179.70$1,976,700.00View SEC Filing  
6/1/2015Mitchell H FinerInsiderSell15,000$190.25$2,853,750.00View SEC Filing  
4/20/2015Mitchell H FinerInsiderSell15,000$126.03$1,890,450.00View SEC Filing  
4/15/2015David DavidsonInsiderSell2,000$130.18$260,360.00View SEC Filing  
4/10/2015Jeffrey T WalshCOOSell21,000$126.21$2,650,410.00View SEC Filing  
4/2/2015Eric SullivanInsiderSell2,998$117.81$353,194.38View SEC Filing  
3/10/2015Jeffrey T WalshCOOSell10,500$110.06$1,155,630.00View SEC Filing  
3/2/2015David DavidsonInsiderSell4,000$94.84$379,360.00View SEC Filing  
1/12/2015Jeffrey T WalshCOOSell10,500$103.57$1,087,485.00View SEC Filing  
1/2/2015David DavidsonInsiderSell4,000$90.01$360,040.00View SEC Filing  
12/19/2014John MaraganoreDirectorBuy2,352$85.00$199,920.00View SEC Filing  
12/10/2014Jeffrey T WalshCOOSell43,500$78.06$3,395,610.00View SEC Filing  
12/8/2014David DavidsonInsiderSell15,000$46.10$691,500.00View SEC Filing  
12/3/2014David DavidsonInsiderSell3,000$41.65$124,950.00View SEC Filing  
12/1/2014Mitchell H FinerInsiderSell18,000$39.70$714,600.00View SEC Filing  
12/1/2014Nick LeschlyCEOSell2,417$39.70$95,954.90View SEC Filing  
11/3/2014David DavidsonInsiderSell3,000$41.68$125,040.00View SEC Filing  
11/3/2014Nick LeschlyCEOSell25,000$41.68$1,042,000.00View SEC Filing  
10/24/2014Nick LeschlyCEOSell33,900$40.22$1,363,458.00View SEC Filing  
10/10/2014Jeffrey T WalshCOOSell7,500$33.16$248,700.00View SEC Filing  
10/9/2014Steven GillisDirectorSell115,000$35.25$4,053,750.00View SEC Filing  
10/8/2014Mitchell H FinerInsiderSell34,518$33.52$1,157,043.36View SEC Filing  
10/7/2014Steven GillisDirectorSell57,435$35.43$2,034,922.05View SEC Filing  
10/2/2014Steven GillisDirectorSell91,165$35.28$3,216,301.20View SEC Filing  
10/1/2014David DavidsonInsiderSell3,000$34.55$103,650.00View SEC Filing  
10/1/2014Nick LeschlyCEOSell8,000$34.55$276,400.00View SEC Filing  
9/12/2014Robert I TepperDirectorSell125,000$36.54$4,567,500.00View SEC Filing  
9/10/2014Jeffrey T WalshCOOSell7,500$37.02$277,650.00View SEC Filing  
9/2/2014David DavidsonInsiderSell3,000$38.00$114,000.00View SEC Filing  
9/2/2014Nick LeschlyCEOSell10,300$38.45$396,035.00View SEC Filing  
8/11/2014Jeffrey T WalshCOOSell7,500$34.26$256,950.00View SEC Filing  
8/1/2014David DavidsonInsiderSell3,000$33.62$100,860.00View SEC Filing  
8/1/2014Nick LeschlyCEOSell8,000$33.62$268,960.00View SEC Filing  
7/14/2014John MaraganoreDirectorBuy2,941$34.00$99,994.00View SEC Filing  
7/10/2014Jeffrey T WalshCOOSell7,500$33.20$249,000.00View SEC Filing  
7/3/2014Nick LeschlyCEOSell22,283$39.86$888,200.38View SEC Filing  
7/1/2014David DavidsonInsiderSell3,000$39.55$118,650.00View SEC Filing  
6/20/2014Nick LeschlyCEOSell17,075$40.06$684,024.50View SEC Filing  
6/16/2014Jeffrey T WalshCOOSell1,500$39.86$59,790.00View SEC Filing  
6/16/2014Mitchell H FinerInsiderSell10,000$39.84$398,400.00View SEC Filing  
6/16/2014Nick LeschlyCEOSell42,925$40.02$1,717,858.50View SEC Filing  
6/10/2014Jeffrey T WalshCOOSell6,000$24.23$145,380.00View SEC Filing  
6/2/2014Mitchell H FinerInsiderSell8,000$22.21$177,680.00View SEC Filing  
6/2/2014Nick LeschlyCEOSell5,000$22.21$111,050.00View SEC Filing  
5/14/2014Jeffrey WalshCOOSell1,500$20.03$30,045.00View SEC Filing  
5/12/2014Jeffrey WalshCOOSell4,500$18.93$85,185.00View SEC Filing  
5/1/2014David DavidsonInsiderSell4,000$19.85$79,400.00View SEC Filing  
5/1/2014Nick LeschlyCEOSell5,000$20.07$100,350.00304,318View SEC Filing  
4/10/2014Jeffrey WalshCOOSell6,000$21.29$127,740.00View SEC Filing  
1/22/2014Linda BainVPSell2,500$25.11$62,775.00View SEC Filing  
1/17/2014Robert TepperDirectorSell307,000$22.43$6,886,010.00View SEC Filing  
1/16/2014Mitchell FinerInsiderSell10,000$23.52$235,200.00View SEC Filing  
1/14/2014Robert TepperDirectorSell340,000$21.90$7,446,000.00View SEC Filing  
1/10/2014Jeffrey WalshCOOSell6,000$21.98$131,880.00View SEC Filing  
1/3/2014David DavidsonInsiderSell15,000$20.88$313,200.00View SEC Filing  
1/3/2014Linda BainVPSell5,000$20.89$104,450.00View SEC Filing  
(Data available from 1/1/2013 forward)


bluebird bio (NASDAQ BLUE) News Headlines

Janney Montgomery Scott Analysts Give bluebird bio (BLUE) a $125.00 Price TargetJanney Montgomery Scott Analysts Give bluebird bio (BLUE) a $125.00 Price Target - April 20 at 1:55 PM
Why Investment Wealth-Builders Disdain Big Pharma Stocks NowWhy Investment Wealth-Builders Disdain Big Pharma Stocks Now - April 20 at 10:45 AM
Is bluebird bio One Step Closer to Its First Commercial Drug?Is bluebird bio One Step Closer to Its First Commercial Drug? - April 20 at 10:45 AM
Gene therapy helps patients avoid blood transfusion, study saysGene therapy helps patients avoid blood transfusion, study says - April 19 at 10:30 AM
bluebird bio Announces New England Journal of Medicine Publication of Interim Data from Two Phase 1/2 Clinical Studies of LentiGlobinTM Gene Therapy in Patients with Transfusion-Dependent β-Thalassemiabluebird bio Announces New England Journal of Medicine Publication of Interim Data from Two Phase 1/2 Clinical Studies of LentiGlobinTM Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia - April 19 at 10:30 AM
Gene Therapy Shows Promise in Patients with a Blood DisorderGene Therapy Shows Promise in Patients with a Blood Disorder - April 19 at 10:30 AM
bluebird bio (BLUE) Price Target Raised to $232.00bluebird bio (BLUE) Price Target Raised to $232.00 - April 19 at 9:04 AM
bluebird bio Inc (BLUE) Insider Sells $540,510.00 in Stockbluebird bio Inc (BLUE) Insider Sells $540,510.00 in Stock - April 16 at 7:33 PM
Sanford C. Bernstein Initiates Coverage on bluebird bio (BLUE)Sanford C. Bernstein Initiates Coverage on bluebird bio (BLUE) - April 15 at 3:59 PM
Is bluebird bio, Inc. a Buy on the Dip?Is bluebird bio, Inc. a Buy on the Dip? - April 15 at 3:54 PM
bluebird bio (BLUE) Downgraded by BidaskClubbluebird bio (BLUE) Downgraded by BidaskClub - April 14 at 8:31 AM
bluebird bios (BLUE) Buy Rating Reaffirmed at BMO Capital Marketsbluebird bio's (BLUE) Buy Rating Reaffirmed at BMO Capital Markets - April 13 at 12:03 PM
Exploring Voyager Therapeutics’ Cash Flows and Valuation MetricsExploring Voyager Therapeutics’ Cash Flows and Valuation Metrics - April 13 at 10:49 AM
bluebird bio (BLUE) Upgraded to "Hold" by BidaskClubbluebird bio (BLUE) Upgraded to "Hold" by BidaskClub - April 11 at 10:10 PM
Why Omeros Stock Rose Last WeekWhy Omeros Stock Rose Last Week - April 11 at 3:45 PM
$5.77 Million in Sales Expected for bluebird bio Inc (BLUE) This Quarter$5.77 Million in Sales Expected for bluebird bio Inc (BLUE) This Quarter - April 10 at 2:38 AM
-$2.00 Earnings Per Share Expected for bluebird bio Inc (BLUE) This Quarter-$2.00 Earnings Per Share Expected for bluebird bio Inc (BLUE) This Quarter - April 8 at 5:20 PM
bluebird bio (BLUE) Rating Lowered to Underweight at Morgan Stanleybluebird bio (BLUE) Rating Lowered to Underweight at Morgan Stanley - April 8 at 3:17 PM
bluebird bio (BLUE) Upgraded at Evercore ISIbluebird bio (BLUE) Upgraded at Evercore ISI - April 7 at 10:19 AM
4 Biotechs Ready for Big Rebounds4 Biotechs Ready for Big Rebounds - April 5 at 8:22 AM
bluebird bio Inc (BLUE) Insider David Davidson Sells 22,000 Sharesbluebird bio Inc (BLUE) Insider David Davidson Sells 22,000 Shares - April 4 at 10:22 PM
bluebird bio (BLUE) PT Raised to $162.00bluebird bio (BLUE) PT Raised to $162.00 - April 4 at 1:20 PM
bluebird bio (BLUE) Lowered to "Sell" at BidaskClubbluebird bio (BLUE) Lowered to "Sell" at BidaskClub - April 4 at 9:55 AM
ValuEngine Upgrades bluebird bio (BLUE) to "Buy"ValuEngine Upgrades bluebird bio (BLUE) to "Buy" - April 3 at 7:01 PM
Biotech Analysis Central Pharma News: bluebird Bio Teams Up; Galectins Advance; Pfizers Late-Stage WinBiotech Analysis Central Pharma News: bluebird Bio Teams Up; Galectin's Advance; Pfizer's Late-Stage Win - April 3 at 3:44 PM
Why Did Regeneron Pharmaceuticals’ Stock Price Rise Last Week?Why Did Regeneron Pharmaceuticals’ Stock Price Rise Last Week? - April 3 at 3:43 PM
BTIG Research Upgrades bluebird bio (BLUE) to BuyBTIG Research Upgrades bluebird bio (BLUE) to Buy - April 2 at 8:21 AM
bluebird bios (BLUE) "Outperform" Rating Reaffirmed at Wedbushbluebird bio's (BLUE) "Outperform" Rating Reaffirmed at Wedbush - April 2 at 12:30 AM
bluebird bio (BLUE) Given Buy Rating at Maxim Groupbluebird bio (BLUE) Given Buy Rating at Maxim Group - April 1 at 11:24 PM
bluebird bio (BLUE) Price Target Raised to $162.00 at Barclaysbluebird bio (BLUE) Price Target Raised to $162.00 at Barclays - April 1 at 10:52 PM
bluebird bio Inc (BLUE) Receives Average Recommendation of "Hold" from Brokeragesbluebird bio Inc (BLUE) Receives Average Recommendation of "Hold" from Brokerages - April 1 at 11:38 AM
Celgene (CELG) Up on Deal With bluebird For CAR-T CandidateCelgene (CELG) Up on Deal With bluebird For CAR-T Candidate - March 29 at 10:56 AM
bluebird bio (BLUE) Rating Reiterated by Canaccord Genuitybluebird bio (BLUE) Rating Reiterated by Canaccord Genuity - March 28 at 9:16 PM
bluebird bio (BLUE), Celgene (CELG) Enter Agreement to Co-Develop and Co-Promote bb2121bluebird bio (BLUE), Celgene (CELG) Enter Agreement to Co-Develop and Co-Promote bb2121 - March 28 at 3:39 PM
Celgene Shares Higher on Co-Development Pact With BluebirdCelgene Shares Higher on Co-Development Pact With Bluebird - March 28 at 3:39 PM
bluebird bio and Celgene Corporation Enter into Agreement to Co-Develop and Co-Promote Anti-BCMA CAR T Cell Therapy bb2121 in the United Statesbluebird bio and Celgene Corporation Enter into Agreement to Co-Develop and Co-Promote Anti-BCMA CAR T Cell Therapy bb2121 in the United States - March 28 at 10:27 AM
BidaskClub Lowers bluebird bio (BLUE) to BuyBidaskClub Lowers bluebird bio (BLUE) to Buy - March 28 at 12:34 AM
bluebird bio (BLUE) Downgraded by BidaskClub to Holdbluebird bio (BLUE) Downgraded by BidaskClub to Hold - March 24 at 10:59 AM
 Brokerages Anticipate bluebird bio Inc (BLUE) Will Post Quarterly Sales of $5.77 Million Brokerages Anticipate bluebird bio Inc (BLUE) Will Post Quarterly Sales of $5.77 Million - March 24 at 4:30 AM
Analysts’ Recommendations for Akcea and Its Peers in MarchAnalysts’ Recommendations for Akcea and Its Peers in March - March 21 at 3:55 PM
bluebird bio (BLUE) Price Target Raised to $209.00bluebird bio (BLUE) Price Target Raised to $209.00 - March 21 at 12:06 PM
This Is My Favorite Biotech Stock To Buy On SaleThis Is My Favorite Biotech Stock To Buy On Sale - March 21 at 11:21 AM
bluebird bio (BLUE) Upgraded at Zacks Investment Researchbluebird bio (BLUE) Upgraded at Zacks Investment Research - March 20 at 7:10 PM
Mark Vachon Sells 6,000 Shares of bluebird bio Inc (BLUE) StockMark Vachon Sells 6,000 Shares of bluebird bio Inc (BLUE) Stock - March 19 at 4:14 PM
bluebird bio Inc to Post Q1 2019 Earnings of ($2.31) Per Share, William Blair Forecasts (BLUE)bluebird bio Inc to Post Q1 2019 Earnings of ($2.31) Per Share, William Blair Forecasts (BLUE) - March 19 at 6:46 AM
bluebird bio (BLUE) Presents At Barclays Global Healthcare Conference 2018 - Slideshowbluebird bio (BLUE) Presents At Barclays Global Healthcare Conference 2018 - Slideshow - March 17 at 11:19 AM
bluebird bio (BLUE) Downgraded to "Buy" at BidaskClubbluebird bio (BLUE) Downgraded to "Buy" at BidaskClub - March 17 at 12:06 AM
bluebird bio (BLUE) Rating Reiterated by William Blairbluebird bio (BLUE) Rating Reiterated by William Blair - March 16 at 4:27 PM
UBS Group Begins Coverage on bluebird bio (BLUE)UBS Group Begins Coverage on bluebird bio (BLUE) - March 16 at 3:57 PM
Janney Says Bluebirds Therapies Are Encouraging, But Stock Is Fairly Valued - BenzingaJanney Says Bluebird's Therapies Are 'Encouraging,' But Stock Is Fairly Valued - Benzinga - March 15 at 3:45 PM

SEC Filings

bluebird bio (NASDAQ:BLUE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


bluebird bio (NASDAQ:BLUE) Income Statement, Balance Sheet and Cash Flow Statement


bluebird bio (NASDAQ BLUE) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.